Results 31 to 40 of about 3,142,333 (299)
The new drug saxagliptin is now registrated in Russia
Сахарный диабет, 2010 23 ноября в Москве состоялся симпозиум, посвященный появлению в России нового препарата Онглиза (саксаглиптин) из группы ингибиторов дипептидилпептидазы-4 (ДПП-4).
Editorial team Diabetes Mellitus
doaj +1 more source
, 2018 Introduction: Insulin resistance has been proposed to accelerate progression to type 1 diabetes (T1D) in antibody positive relatives of affected individuals.
Misra, Shivani +5 more
core +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Background Japan has one of the highest dialysis prevalence rates worldwide and a shrinking, aging population. Whether dialysis burden has entered a sustained post‐peak phase or whether recent declines partly reflect pandemic‐related disruptions remains uncertain.
Hatice Şahin +2 more
wiley +1 more source
Russian Association of Endocrinologists about the introduction of Diabeton MR (60 mg tablets)
Сахарный диабет, 2011 Хорошо известный препарат Диабетон МВ 30 мг успешно применяется в России и мире для лечения больных сахарным диабетом 2 типа (СД2) с 2000 года. Доказанная эффективность и безопасность Диабетона МВ 30 мг послужила основанием для его широкого применения в ...
Editorial team Diabetes Mellitus
doaj +1 more source
Evaluation of the DiRECT-Australia type 2 diabetes remission service
, 2023 Background: The Diabetes REmission Clinical Trial (DiRECT) study demonstrated that a program including intensive structured total diet replacement (TDR) in UK primary care resulted in high rates of diabetes remission in adults with recent onset type 2 ...
Osuagwu, Uchechukwu L. (R19382) +5 more
core
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Introduction Peritoneal dialysis (PD) is an established home‐based kidney replacement therapy (KRT), but its uptake remains low in Japan. We evaluated whether individualized education in a dedicated outpatient clinic was associated with the initiation of PD.
Yasuko Ito +7 more
wiley +1 more source
Russian Association of Endocrinologists reports commencement of Glimecomb clinical use
Сахарный диабет, 2011 Российская ассоциация эндокринологов информирует о начале применения в клинической практике препарата Глимекомб?. В настоящее время большинство пациентов с сахарным диабетом 2 типа получают комбинированную сахароснижающую терапию.
Editorial team Diabetes Mellitus
doaj +1 more source
Reconstructing enzyme evolution by protein engineering
FEBS Letters, EarlyView.Natural enzyme evolution can be retraced by protein engineering methods such as directed evolution, rational design, and ancestral sequence reconstruction. These approaches reveal how enzymes emerged from ligand‐binding scaffolds, developed varying substrate preferences, formed oligomeric complexes, adapted to environmental changes, and evolved novel ...
Lukas Drexler +2 more
wiley +1 more source
Russian Association of Endocrinologists reports commencement of Amaril clinical use
Сахарный диабет, 2012 1 октября 2011 года в Санкт-Петербурге состоялось официальное представление нового препарата для лечения сахарного диабета 2 типа (СД2) ? Амарил? М (глимепирид+метформин). Препарат зарегистрирован в России 11 января 2011 года и в настоящее время доступен
Editorial team Diabetes Mellitus
doaj +1 more source
Sestrin2 in diabetes and diabetic complications
Frontiers in Endocrinology, 2023 Diabetes is a global health problem which is accompanied with multi-systemic complications. It is of great significance to elucidate the pathogenesis and to identify novel therapies of diabetes and diabetic complications. Sestrin2, a stress-inducible protein, is primarily involved in cellular responses to various stresses.
Xiaodan Zhang +5 more
openaire +3 more sources